Tirofiban After Tenecteplase in Stroke
Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.
-
By
-
Kathryn Wighton
-
May 14, 2026
-
Clinical Scorecard: Tirofiban After Tenecteplase in Stroke
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients with acute ischemic stroke without large- or medium-vessel occlusion or cardioembolic source; excluded those with intracranial hemorrhage. |
| Care Setting | |
Key Highlights
Guideline-Based Recommendations
Diagnosis
Management
- I
- n
- c
- l
- u
- d
- e
-
- d
- e
- f
- i
- n
- i
- t
- i
- o
- n
-
- o
- f
-
- '
- i
- n
- a
- d
- e
- q
- u
- a
- t
- e
-
- c
- l
- i
- n
- i
- c
- a
- l
-
- r
- e
- s
- p
- o
- n
- s
- e
- '
-
- a
- s
-
- n
- o
-
- m
- e
- a
- n
- i
- n
- g
- f
- u
- l
-
- N
- I
- H
- S
- S
-
- s
- c
- o
- r
- e
-
- c
- h
- a
- n
- g
- e
- .
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Tirofiban is off-label for acute ischemic stroke but shows promise as adjunctive therapy; context on its use in myocardial infarction.
Clinical Best Practices
Related Resources & Content
